1. Home
  2. OTEX vs CRSP Comparison

OTEX vs CRSP Comparison

Compare OTEX & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Open Text Corporation

OTEX

Open Text Corporation

HOLD

Current Price

$28.06

Market Cap

6.2B

Sector

Technology

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$48.70

Market Cap

5.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTEX
CRSP
Founded
1991
2013
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
5.2B
IPO Year
1998
2016

Fundamental Metrics

Financial Performance
Metric
OTEX
CRSP
Price
$28.06
$48.70
Analyst Decision
Hold
Buy
Analyst Count
12
23
Target Price
$27.95
★ $85.63
AVG Volume (30 Days)
1.2M
★ 1.4M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 4.01%
N/A
EPS Growth
★ 56.36
N/A
EPS
★ 2.58
N/A
Revenue
★ $2,815,241,000.00
$289,590,000.00
Revenue This Year
N/A
$1,052.09
Revenue Next Year
$1.67
$273.88
P/E Ratio
$10.81
★ N/A
Revenue Growth
22.88
★ 9169.85
52 Week Low
$19.78
$44.12
52 Week High
$39.81
$67.66

Technical Indicators

Market Signals
Indicator
OTEX
CRSP
Relative Strength Index (RSI) 80.34 39.37
Support Level $21.79 $45.61
Resistance Level N/A $60.71
Average True Range (ATR) 0.77 2.49
MACD 0.49 -0.26
Stochastic Oscillator 99.66 11.41

Price Performance

Historical Comparison
OTEX
CRSP

About OTEX Open Text Corporation

Open Text Corp provides data management for enterprise AI, offering a secure data foundation and trusted context for credible AI outcomes across private, public, and sovereign cloud, managed cloud services, API, and on-premises environments. The Company also provides cybersecurity solutions to protect sensitive data, applications and systems across complex hybrid environments, including identity and access management, threat detection and response, data protection and application security. It serves private, public, and regulated sectors, including retail, financial services, government, manufacturing, healthcare, energy, and logistics, with clients. Geographically, it derives maximum revenue from the Americas.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: